Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies.

Abstract:

Staphyloccus aureus is one of the commonest pathogens to be implicated in both hospital- and community-acquired infections. Methicillin-susceptible S. aureus, (MSSA) and methicillin-resistant S. aureus (MRSA) cause surgical site infections, bacteraemia, pneumonia and catheter-associated infections and are responsible for significant morbidity and mortality. Currently, Bactroban (2% mupirocin) is used for the decolonization of nasal MRSA and for the treatment of skin infections with MRSA. Chlorhexidine digluconate is used to decolonize S. aureus form the skin. The combined effects of mupirocin and chlorhexidine on different carriage sites have successfully controlled endemic and epidemic MRSA infections in intensive care units and significantly reduce surgical site infections.

See http://jac.oxfordjournals.org/ to view full article (ref: doi:10.1093/jac/dks384)

---